2026-10-01T22:55:30Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/121982026-09-30T00:05:54Zcom_10259_11209com_10259_5086com_10259_2604col_10259_11210

Role of Pharmacogenetics in the Treatment of Acute Myeloid Leukemia: Systematic Review and Future Perspectives Pinto Merino, Álvaro Labrador, Jorge Zubiaur, Pablo Alcaraz, Raquel Herrero, María José Montesinos, Pau Abad Santos, Francisco Saiz Rodríguez, Miriam Acute myeloid leukemia Pharmacogenetics Cytarabine Anthracyclines FLT3 inhibitors IDH inhibitors CD33 inhibitors Hypomethylating agents BCL2 inhibitors Acute myeloid leukemia (AML) is a heterogeneous disease characterized by remarkable toxicity and great variability in response to treatment. Plenteous pharmacogenetic studies have already been published for classical therapies, such as cytarabine or anthracyclines, but such studies remain scarce for newer drugs. There is evidence of the relevance of polymorphisms in response to treatment, although most studies have limitations in terms of cohort size or standardization of results. The different responses associated with genetic variability include both increased drug efficacy and toxicity and decreased response or resistance to treatment. A broad pharmacogenetic understanding may be useful in the design of dosing strategies and treatment guidelines. The aim of this study is to perform a review of the available publications and evidence related to the pharmacogenetics of AML, compiling those studies that may be useful in optimizing drug administration. 2026-09-29T09:01:08Z 2026-09-29T09:01:08Z 2026-09-29T09:01:08Z 2022-03 info:eu-repo/semantics/article https://hdl.handle.net/10259/12198 10.3390/PHARMACEUTICS14030559 1999-4923 eng Pharmaceutics. 2022, V. 14, n. 3, art. 559 https://doi.org/10.3390/ pharmaceutics14030559 http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Atribución 4.0 Internacional MDPI